Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-asarone is a naturally occurring phenylpropanoid small molecule extracted from the rhizomes of *Acorus* species, most notably *Acorus tatarinowii* and *Acorus calamus*. It is a research compound that has demonstrated a broad range of pharmacological activities in the central nervous system and metabolic pathways. In China, it is marketed under the brand name Xixinnaojiaonang as an antiepileptic medication. Its mechanism of action is multi-targeted, involving the modulation of GABAergic and glutamatergic neurotransmission, inhibition of voltage-gated sodium channels, and suppression of neuroinflammation through the NF-kappa B pathway. Preclinical studies have also explored its potential as a treatment for depression, anxiety, Parkinson's disease, Alzheimer's disease, and hyperlipidemia, although its clinical utility is currently limited by potential toxicity at higher doses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-asarone.